Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin. It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.
Ropivacaine is indicated in adult patients for the induction of regional or local anesthesia for surgery or acute pain management.
Montefiore Medical Center, Bronx, New York, United States
Clinique du Pré, Le Mans, Pays De La Loire, France
Clinique Bizet, Paris, Ile-de -France, France
CMC Ambroise Paré, Neuilly-sur-Seine, Ile-de-France, France
University of Alberta Hospital, Edmonton, Alberta, Canada
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
KK Women's and Children's Hospital, Singapore, Singapore
Clinique Victor PAUCHET, Amiens, France
Centre Hospitalier de Béthune Beuvry, Béthune, France
Hôpital Privé Sévigné, Rennes, France
Kangnam sacred heart hospital, Seoul, Yeongdeungpo-gu, Korea, Republic of
Yale-New Haven Hospital St Raphael, New Haven, Connecticut, United States
University of Alberta Hospital, Edmonton, Alberta, Canada
Cleveland Clinic, Cleveland, Ohio, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.